Literature DB >> 12559502

The diagnosis of primary progressive multiple sclerosis.

Jerry S Wolinsky1.   

Abstract

Primary progressive multiple sclerosis (PPMS) is a rather unique form of the more common relapsing inflammatory demyelinative disease. The absence of attacks that typify relapsing forms of MS imposes special challenges for diagnosis, but also provides an opportunity to study the pathogenesis of the more progressive aspects of the disease process in isolation of confounding transient clinical events. In this review, recent advances in diagnostic approaches are considered in relationship to baseline data from a large multinational study designed to better characterize and treat this clinical phenotype. PPMS subjects with cerebral spinal fluid (CSF) findings consistent with intrathecal immunoglobulin production may have a more tissue destructive disease process than those whose CSF lacks evidence of a B-cell immunopathogenic disease component.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12559502     DOI: 10.1016/s0022-510x(02)00346-5

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  12 in total

1.  Discriminant analysis of the cognitive performance profile of MS patients differentiates their clinical course.

Authors:  Jürgen A Kraus; Cathleen Schütze; Barbara Brokate; Beate Kröger; Günther Schwendemann; Helmut Hildebrandt
Journal:  J Neurol       Date:  2005-03-06       Impact factor: 4.849

2.  [Revision of McDonald's new diagnostic criteria for multiple sclerosis].

Authors:  H Wiendl; B C Kieseier; R Gold; R Hohlfeld; M Bendszus; H-P Hartung
Journal:  Nervenarzt       Date:  2006-10       Impact factor: 1.214

3.  Standardized MR imaging protocol for multiple sclerosis: Consortium of MS Centers consensus guidelines.

Authors:  J H Simon; D Li; A Traboulsee; P K Coyle; D L Arnold; F Barkhof; J A Frank; R Grossman; D W Paty; E W Radue; J S Wolinsky
Journal:  AJNR Am J Neuroradiol       Date:  2006-02       Impact factor: 3.825

4.  Current issues in immunomodulatory treatment of multiple sclerosis--a practical approach.

Authors:  Martin Stangel; Ralf Gold; Achim Gass; Judith Haas; Stefan Jung; Wolfgang Elias; Uwe K Zettl
Journal:  J Neurol       Date:  2006-02       Impact factor: 4.849

5.  Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis.

Authors:  Melih Tutuncu; Junger Tang; Nuhad Abou Zeid; Nilufer Kale; Daniel J Crusan; Elizabeth J Atkinson; Aksel Siva; Sean J Pittock; Istvan Pirko; B Mark Keegan; Claudia F Lucchinetti; John H Noseworthy; Moses Rodriguez; Brian G Weinshenker; Orhun H Kantarci
Journal:  Mult Scler       Date:  2012-06-26       Impact factor: 6.312

Review 6.  Primary progressive multiple sclerosis : current and future treatment options.

Authors:  Siobhan M Leary; Alan J Thompson
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 7.  Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action.

Authors:  Patrice H Lalive; Oliver Neuhaus; Mahdia Benkhoucha; Danielle Burger; Reinhard Hohlfeld; Scott S Zamvil; Martin S Weber
Journal:  CNS Drugs       Date:  2011-05       Impact factor: 5.749

8.  Functional response to active and passive ankle movements with clinical correlations in patients with primary progressive multiple sclerosis.

Authors:  O Ciccarelli; A T Toosy; J F Marsden; C M Wheeler-Kingshott; D H Miller; P M Matthews; A J Thompson
Journal:  J Neurol       Date:  2006-04-20       Impact factor: 4.849

9.  Progressive Onset Multiple Sclerosis: Demographic, Clinical and Laboratory Characteristics of Patients With and Without Relapses in the Course.

Authors:  Bahar Kaymakamzade; Ahmet Kasım Kiliç; Aslı Tuncer Kurne; Rana Karabudak
Journal:  Noro Psikiyatr Ars       Date:  2018-07-04       Impact factor: 1.339

10.  Is inflammation important in early PPMS? a longitudinal MRI study.

Authors:  G T Ingle; J Sastre-Garriga; D H Miller; A J Thompson
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-09       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.